Landier, Wendy http://orcid.org/0000-0003-3319-5652
Bhatia, Smita
Richman, Joshua S.
Campos Gonzalez, Paula D.
Cherven, Brooke
Chollette, Veronica
Aye, Jamie
Castellino, Sharon M.
Gramatges, Maria M.
Lindemulder, Susan
Russell, Thomas B.
Turcotte, Lucie M.
Colditz, Graham A.
Gilkey, Melissa B.
Klosky, James L.
Funding for this research was provided by:
National Cancer Institute (U01CA246567)
Article History
Received: 18 June 2022
Accepted: 21 August 2022
First Online: 12 September 2022
Declarations
:
: The study described in this manuscript was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board (IRB-300005305), with UAB serving as the single IRB (sIRB) of record. In accordance with the SMART (Streamlined, Multisite, Accelerated Resources for Trials) IRB reliance model, participating sites ceded review to the UAB IRB as the Reviewing IRB under the Master Common Reciprocal IRB Authorization Agreement. Healthcare providers eligible for study participation receive an email from the study coordinating center with an information sheet, along with a link to an online survey. The IRB has authorized waiver of consent documentation; thus, completion of the survey implies consent. An item on the survey will ask the healthcare provider if they wish to participate in study interviews. Those indicating interest in interview participation are contacted by the study Clinical Research Assistant (CRA) at the study coordinating center via email or telephone. Verbal consent is obtained prior to interview initiation. There is no interaction between the study team and cancer survivors. Study involvement includes abstraction of existing clinical information only done by the site CRA under a HIPAA waiver as part of each site’s Quality Improvement initiative.
: Not applicable.
: The authors declare no competing interests.